Recently, constitutive activation of JAK kinases (JAKs) and/or signal transducers and activators of transcription (STATs) has been reported in growing numbers of human cancer cells as well as oncogene-transformed cells. JAB/SOCS-1 has been shown to be an intrinsic JAK tyrosine kinase inhibitor and to suppress the cytokine-dependent JAK ± STAT pathway. In this report, we investigated the eect of ectopic expression of JAB on v-Src-induced JAK ± STAT activation. Forced expression of JAB in v-Src-transformed NIH3T3 cells neither suppressed phosphorylation of STAT3 and JAK1/JAK2 nor blocked STAT3-reporter gene activation. Colony forming assay also showed that JAB did not suppress v-Src-induced transformation of NIH3T3 cells, while dominant negative STAT3 suppressed it. In contrast, JAB could downregulate phosphorylation of STAT1 and STAT3 induced by interferon gamma (IFN g ) and interleukin-6 (IL-6) plus soluble IL6 receptor (sIL-6R), respectively. Furthermore, in vitro kinase assay indicated that JAB suppressed hyperactivation of JAK1/ JAK2 and JAK1 induced by INF g and IL-6 plus sIL-6R respectively, but not v-Src-induced basal JAK1/JAK2 activity. Nevertheless, both JAK1/JAK2 activated by vSrc and that activated by IL-6 plus sIL-6R could similarly bind JAB. These results clearly demonstrate that JAB distinguishes cytokine-induced JAK ± STAT signaling from v-Src-induced one and can not suppress the transformation with v-Src. Oncogene (2000) 19, 4795 ± 4801.
Cytokines exert their biological eect through binding to their cognate cell surface receptors that are associated with subsets of JAK kinases (JAKs). Cytokine-induced receptor dimerization leads to the activation of JAKs, rapid tyrosine phosphorylation of the cytoplasmic domains, and subsequent recruitment of various signaling proteins to the receptor complex (Ihle, 1995) . These signaling proteins include signal transducers and activators of transcription (STAT) family of transcription factors (Ihle, 1996; O'Shea et al., 1997) . The tyrosine-phosphorylated STATs form homo-or hetero-dimers and translocate into the nucleus, where they bind to their speci®c target sequences and regulate the expression of the cytokineinduced genes (Darnell et al., 1994) .
On the other hand, an increasing number of cancer cells have been reported to express STATs molecules, especially STAT3 (Gracia and Jove, 1998) . For example, constitutive activation of STAT1, STAT3, and STAT5 was observed in cells transformed with vSrc or v-Abl, and some malignancies including leukemias, multiple myelomas, head and neck cancers, and breast carcinomas Dainal et al., 1995; Gracia et al., 1997; Grandis et al., 1998; Migone et al., 1995; Yu et al., 1995) . In most of these cases, STATs activation was accompanied by constitutive phosphorylation of JAK1, JAK2, and/or JAK3.
These results suggested that JAK ± STAT signaling would be involved in the malignant transformation of diverse cells. Consistent with this notion, two groups clearly demonstrated that dominant negative (dN) STAT3 suppressed the transformation of ®broblasts by v-Src, suggesting that activation of STAT3 is a critical step in v-Src-transformation (Turkson et al., 1998; Bromberg et al., 1998) . More recently, Niu et al. (1999) reported that electroinjection of dNSTAT3 suppressed growth of the murine melanoma B16 tumor in vivo. Furthermore, Bromberg et al. (1999) demonstrated that the constitutively active form of the STAT3 molecule by itself can mediate cellular transformation.
Previously, JAB (or SOCS-1, SSI-1) was identi®ed as a SH2 domain containing protein that directly binds to the JAK2 kinase (JH1) domain and suppresses members of the JAK family of tyrosine kinases (Endo et al., 1997; Starr et al., 1997; Naka et al., 1997) . Mutational analysis and biochemical characterization revealed a novel type of inhibition of JAK2 tyrosine kinase activity through the two independent binding sites of JAB: the N-terminal kinase inhibitory region (KIR) to the catalytic groove of JH1 and the SH2 domain to the phosphorylated tyrosine residue, Y1007 in the activation loop (Yasukawa et al., 1999; Nicholson et al., 1999) . Our recent study, as well as knockout mice studies, have suggested that one of the major physiological functions of JAB is the negative regulation of the interferon gamma (IFN g )/STAT1 pathway (Sakamoto et al., 1998; Marine et al., 1999 . While JAB is physiologically induced by subset of cytokines, forced expression of JAB drastically downregulates a variety of cytokine-dependent JAK kinase activity to suppress subsequent STATs activation (Endo et al., 1997) . In this context, we had a great interest in whether JAB can inhibit vSrc-induced STAT3 activation and cellular transformation.
To address this issue, we introduced a vector expressing Myc-epitope-tagged JAB (Endo et al., 1997) into v-Src ± NIH3T3 (SRD) cells and established two high expressers of JAB (JSRD1, JSRD2) ( Figure  1a) . We ®rst examined the tyrosine phosphorylation of STAT3 and JAK1, JAK2. As shown in Figure 1b , similar levels of phosphorylation on tyrosine 705 of STAT3 were detected in SRD, JSRD1 and JSRD2 cells. As shown in Figure 1c ,d, JAK1 and JAK2 in JSRD1 and JSRD2 (JSRD1/2) cells was tyrosinephosphorylated at levels similar to those in SRD cells. These results indicated that forced expression of JAB suppressed tyrosine phosphorylation of neither STAT3 nor JAK1/JAK2 in v-Src-transformed cells.
Next, we investigated STAT3 activation by using a reporter gene construct containing interleukin 6 (IL-6) responsive acute phase responsive element (APRE). Reporter gene construct was transfected into NIH3T3 cells, SRD cells, and JSRD cells. As shown in Figure  2a , the luciferase activity of SRD cells was about 16 times higher than that of NIH3T3 cells. Notably, both JSRD1 and JSRD2 cells showed high luciferase activity of levels similar to that of SRD cells. We also assayed the eect of JAB on v-Src-induced STAT3 activation using transient expression in COS7 cells. Expression of the v-Src gene drastically increased STAT3-luciferase activity ( Figure 2b , column 2). While co-expression of JAB suppressed the activity to some extent ( Figure 2b , column 3), a non-functional mutant of JAB, dN75JAB (Yasukawa et al., 1999) also decreased the activity to a similar level (Figure 2b , column 4). Therefore this suppression would not be due to the direct eect of JAB as the JAK inhibitor. In contrast, dominant negative STAT3 (dNSTAT3), of which 705 tyrosine is mutated to phenylalanine, drastically inhibited the luciferase activity ( Figure 2b , column 5). Thus, forced expression of JAB could not suppress v-Src-induced STAT3 activation in either stable or transient transfectants.
JSRD cells were morphologically indistinguishable from SRD cells ( Figure 3a ) and proliferated in soft (Endo et al., 1997) to SRD cells using Lipofectamine (Gibco) followed by selection with 400 mg of G418 (Gibco) per ml. Total cell lysates were prepared as described (Hamaguchi et al., 1993) . Lysates of SRD (lane 1), JSRD1 (lane 2) and JSRD2 (lane 3) were subjected to gel electrophoresis followed by immunoblotting with anti-Myc antibody (aMyc) (Invitrogen). (Figure 3b ). These results suggest that JAB cannot reverse the malignant phenotype of v-Src-transformed cells. As the introduction of dNSTAT3 into v-Src-transformed NIH3T3 cells suppresses the cell proliferation in soft agar (Bromberg et al., 1998) , JAB and dNSTAT3 also seem to dier in the inhibitory eect for transformation. However, the possibility remained that JAB might disturb the initial step of transformation. To exclude this possibility, we co-transfected the expression vectors for v-Src and JAB into NIH3T3 cells and plated the transfectants in soft agar. As shown in Figure 3c , there was no signi®cant dierence in the number of colonies between mock transfectants and JAB transfectants. In contrast, as reported previously (Turkson et al., 1998; Bromberg et al., 1998) , supplementation of the expression vector for dNSTAT3 signi®cantly inhibited colony formation. These data indicate that JAB can not suppress the transformation activity of v-Src, consistent with the biochemical data described above. The ®nding that JAB could not inhibit v-Src-induced JAK ± STAT3 activation was rather unexpected because JAB has been shown to be a strong inhibitor for JAKs. v-Src might directly phosphorylate STAT3 but not through JAKs (Cao et al.; 1996; Chaturvedi et al., 1998) . However, this idea alone could not explain why JAKs were still phosphorylated even if JAB was highly expressed. In SRD cells, JAKs might be too vigorously activated to be suppressed by JAB, or JAB would be inactivated by unknown mechanisms. To see whether JAB is still functional as a JAK inhibitor in JSRD cells, we stimulated SRD and JSRD cells with cytokines, IFNg or IL-6 plus soluble IL-6 receptor (sIL-6R). In NIH3T3 cells, IFNg and IL-6 plus sIL-6R are known to stimulate STAT1 and STAT3, respectively. In SRD cells, 701 tyrosine (Y701) of STAT1 is not phosphorylated without stimulation (Figure 4a , lane 1) because v-Src does not activate STAT1 (Yu et al., 1995) . Upon stimulation with IFNg, Y701 of STAT1 of SRD cells was phosphorylated (Figure 4a , lane 2). On the other hand, the phosphorylation of STAT1 was signi®cantly suppressed in JSRD 1/2 cells (Figure 4a , lanes 4 and 6). Then we stimulated these cells with IL-6 plus sIL-6R. Although 705 tyrosine of STAT3 was basally phosphorylated in SRD cells even without cytokine stimulation, the phosphorylation level was augmented with the stimulation (Figure 4b ; lane 2). On the other hand, this augmentation was downregulated in JSRD 1/2 cells (Figure 4b, lanes 4 and 6) . Thus, the constitutive expression of JAB suppressed the tyrosine phosphorylation of STAT1 and STAT3 induced by IFNg and IL-6 plus sIL-6R, respectively, although v-Src-induced basal phosphorylation of STAT3 was not altered. These results suggest that JAB in JSRD cells still can suppress STATs activation.
Next, to investigate whether STATs activation correlates to activities of JAKs, we checked in vitro kinase activity of JAK1 and JAK2. As Campbell et al. (1997) reported, autophosphorylation of both JAK1 and JAK2 was upregulated in SRD cells compared to that of the control NIH3T3 cells (Figure 4c ± f; lanes 2). While they reported that autophosphorylation of JAK1 was much stronger than that of JAK2 in v-Srctransformed cells, we detected distinctly autophosphorylated JAK2. This might be due to the dierence of cell lines or antibodies utilized for immunoprecipitation. Whereas the activity of both JAK1 and JAK2 was enhanced upon stimulation of IFNg in SRD cells (Figure 4c ,e; lanes 3), only JAK1 activity was augmented with IL-6 plus sIL-6R (Figure 4d,f; lanes  3 ). This pro®le of JAK1/JAK2 autophosphorylation is admissible since knockout mice studies suggested that JAK1 but not JAK2 is indispensable for gp130/IL-6 receptor signaling while both JAK1 and JAK2 are ) were transfected with a plasmid containing 0.5 mg reporter gene carrying APRE-promoter . Thirty six hours after transfection, luciferase assays were performed using dual-luciferase reporter system (Promega), and the results indicate luciferase activities normalized against an internal control luciferase reporter of Renilla luciferase (Promega). Values are means plus standard deviations of three independent experiments. (b) COS7 cells (2610 5 ) were transfected with a plasmid mixture containing 0.5 mg reporter gene plus 0.5 mg of a pcDNA3 ± STAT3, which was constructed from HA ± STAT3 (Nakajima et al., 1996) , and expression vectors as indicated. The plasmid of dNSTAT3 was constructed by oligonucleotide-mediated PCR methods. Amount of plasmids was supplemented with empty vectors. Values are means plus standard deviations of three independent experiments required for IFNg signaling (Rodig et al., 1998; Parganas et al., 1998) . Consistent with the results of tyrosyl phosphorylation in Figure 1c (2610 6 cells) in 100 mm diameter dish were transfected with pBabe-puro/v-src with empty vector (column 1), pcDNA3-Myc-JAB (column 2) or pcDNA3-Myc-dNSTAT3 (column 3). Forty-eight hours after transfection, half of cells were plated into 0.36 % soft agar with 8% Calf Serum (CS) and another half were fed with Dulbecco's modi®ed Eagle's medium (DMEM) plus 8% CS containing 2 mg of puromycin (Sigma) and 400 mg of G418 per ml. Colonies were counted 20 days after the transfection. The number of colonies in soft agar was normalized against that in DMEM containing antibiotics to eliminate the bias of transfection eciency. Values were means plus standard deviations of ®ve independent experiments. Percent colony formation is relative to that induced by pBabepuro/v-src with empty vector. No colonies were detected in the control plates with empty vector only together, these results suggest that the capacity of JAB in JSRD cells is not yet exhausted and that JAB has a de®nite preference for JAK ± STAT signaling triggered by cytokine stimulation over than that by v-Src.
Why could JAB not inhibit the activation of JAKs that was evoked by v-Src? JAB binds the activation loop of JH1 domain of JAKs and suppresses the kinase activity when stimulated with cytokines (Yasukawa et al., 1999) . Therefore, it is possible that JAB might not bind JAKs phosphorylated by v-Src. However, this is not the case. To examine the binding, we performed co-precipitation experiments of JAB using aJAK1 or aJAK2 ( Figure 5) . For a control, we established a NIH3T3 cell line (JNIH) that expressed JAB as strongly as JSRD1/2. (Figure 5 , lane 2) In JNIH cells, weak association between JAB and JAK1/JAK2 was detected even with no stimulation (Figure 5 , lanes 3 and 6). When stimulated with IL-6 plus sIL-6R, the association signi®cantly increased probably due to the enhanced interaction between tyrosine phosphorylated JH1 domain and SH2 domain of JAB ( Figure 5 , lanes 4 and 7) (Yasukawa et al., 1999) . In JSRD1 cells, JAB 5 cells were deprived of serum for 4 h and treated with recombinant murine IFNg (Pepro Tech EC Ltd.) (+; 100 mg per ml, 7; none). Fifteen min later, the cells were harvested and the total cell lysates were subjected to immunoblot analysis using anti-phospho-STAT1 (Tyr701) antibody (New England Biolabs, Inc.) (apY701) (upper panel) or anti-STAT1 antibody (New England Biolabs, Inc.) (aSTAT1) (lower panel). (b) Same procedure as (a) was performed except for the following steps. Cells were treated with recombinant human IL-6 (+; 100 ng per ml, 7; none) plus recombinant human sIL-6R (R&D Systems Inc) (+; 100 ng per ml, 7; none) and analysed using apY705 (upper panel) or aSTAT3 (lower panel). (c ± f) In vitro kinase assay for autophosphorylation of JAK1/2. Two610 6 cells were treated with cytokines by the same procedure as (a,b) and were lysed with lysis buer. Lysates were subjected to immunoprecipitation using aJAK1 (c,d) or aJAK2 (e,f). Immunoprecipitates were washed twice with lysis buer and once with phosphorylation buer (50 mM HEPES, pH 7.6, 0.1% Triton X-100, 0.5% dithiothretiol, 6.25 mM magnesium chloride, 100 mM NaCl) and incubated for autophosphorylation in phosphorylation buer containing [g 32 P]ATP (370 kBq) (NEN) as described (Campbell et al., 1997) . The reaction mixtures were washed twice with phosphorylation buer containing 10 mM EDTA, electrophoresed on an SDS-8% polyacrylamide gel, and were analysed by BAS 2000 system (upper panel). Equal amount of precipitates were subjected for immunoblotting (lower panel) was co-immunoprecipitated at levels similar to those in stimulated JNIH cells ( Figure 5, lanes 5 and 8) . These data suggest that JAB could bind JAK1/JAK2 activated by v-Src as strongly as that activated by IL-6.
Although it is believed that IFNg and IL-6 dimerize interferon receptor and gp130, respectively, and subsequently activate JAK1/JAK2 to induce interJAKs transphosphorylation (O'Shea et al., 1997) , the process in which v-Src activates JAK1/JAK2 has not been clari®ed. As it has been shown that v-Src associates with JAK1 (Campbell et al., 1997) , it seems feasible that v-Src directly transphosphorylates JAK1/ JAK2 without the process of inter-JAKs transphosphorylation. From this point of view, JAB might speci®cally inhibit inter-JAKs but not v-Src ± JAKs transphosphorylation. Interestingly, it was previously shown that the kinase inhibitory region (KIR) of JAB resembles the activation loop of JAKs (Yasukawa et al., 1999) . Therefore, JAB may interfere with interJAKs transphosphorylation by functioning as a pseudo-substrate for JAKs but not for v-Src. Further studies should elucidate this point.
In summary, we report here that v-Src activates JAK ± STAT3 signaling and transforms NIH3T3 cells in a JAB-insensitive manner although cytokinedependent JAK ± STAT pathway is obviously repressed by JAB. Considering the evidence that JAB regulates the cytokine network as a negative modulator, v-Srcinduced JAK ± STAT3 activation and subsequent transformation might escape from cytokine-network surveillance. JSRD cells established here would be a useful tool to dissect the signals of cytokine-dependent and -independent JAK ± STAT activation.
